Fda grants regenerative medicine advanced therapy (rmat) designation for rexlemestrocel-l in chronic low back pain

New york, feb. 08, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the united states food and drug administration's (fda) office of tissues and advanced therapies (otat) has granted regenerative medicine advanced therapy (rmat) designation for rexlemestrocel-l in the treatment of chronic low back pain (clbp) associated with disc degeneration, in combination with hyaluronic acid (ha) as delivery agent for injection into the lumbar disc.
MESO Ratings Summary
MESO Quant Ranking